Clinical Trial Update: Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease [Phase 2]

View source ↗

Summary

A Phase 2 trial of AIN457 for moderate-to-severe Crohn's disease was terminated; results assessing efficacy, safety and tolerability were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• AIN457

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Crohn's Disease | Phase 2 | Status: TERMINATED | Results posted: 2015-03-31